GLP-1 Market: The obesity and diabetes drug race is becoming one of the biggest business stories in global pharma. Reuters reported that analysts now estimate global obesity drug sales around USD 105 billion by 2030, lower than earlier USD 130 billion forecasts because of expected price pressure and changing usage patterns.
IQVIA’s obesity outlook is even more aggressive in range. It reported that the global obesity medicines market reached USD 66 billion in list-price sales in 2025 and is forecast to reach USD 92 billion in 2026, with longer-term estimates ranging from USD 105 billion to USD 200 billion from 2027 onward.
But the payer side is tightening. Reuters reported that Cigna will stop covering GLP-1 weight-loss medicines such as Wegovy and Zepbound for its own employees starting in July 2026, while continuing coverage for type 2 diabetes use. That shows the business tension clearly: patients want access, pharma wants premium pricing, but employers and insurers are questioning affordability.
Witfire View: GLP-1 is not only a drug class. It is a test of pricing power, payer resistance, manufacturing scale and long-term patient retention.
How GLP-1 Drugs Work
GLP-1 medicines work by copying the action of a natural gut hormone called glucagon-like peptide-1. This hormone is released after food intake and helps the body manage blood sugar, appetite, and digestion.
These drugs increase insulin release only when blood glucose is high. This mechanism is important because it reduces sugar more naturally and lowers the risk of unnecessary insulin stimulation. At the same time, they reduce glucagon, a hormone that signals the liver to release glucose. As a result, excess glucose output from the liver is controlled.
Another major action happens in the stomach. GLP-1 drugs slow gastric emptying, which means food moves more slowly from the stomach to the intestine. This helps reduce sudden sugar spikes after meals and keeps the person feeling full for a longer time.
The most commercially powerful effect is appetite control. GLP-1 drugs act on brain pathways involved in hunger and satiety. Patients often feel less hunger, fewer cravings, and smaller meal demand. This is why we now watch these drugs not only as diabetes medicines but also as major obesity and metabolic health products.
The business impact is huge because one drug class is touching multiple markets at once: diabetes, obesity, cardiovascular risk, chronic metabolic disease, insurance spending, manufacturing capacity, and long-term patient adherence. That is why GLP-1 has become one of the most important pharma growth stories of this decade.